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CONCLUSIONS: SSP with perindopril/indapamid saves
lives and Health care costs.
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OBJECTIVES: Accurate information about resources use
and costs of stroke is necessary for informed health plan-
ning activities. The aim of this study was to determine the
patterns of health resources use among stroke patients
and to estimate the total costs (direct medical and non
medical and indirect production losses) of stroke in Spain
for 2001. METHODS: The cost-of-illness method was
used. Direct and indirect costs were estimated using
prevalence costs. Indirect costs (productivity costs) were
estimated using the approach of human capital theory
from lost earning attributable to stroke related mortality
and morbidity. Data on resource use were retrospectively
collected from hospitals and questionnaires. The costs of
stroke during the ﬁrst, second and third year after stroke
and the total costs of stroke were estimated. RESULTS:
We gathered information from 350 patients. The average
cost per stroke survivor during the ﬁrst, second and third
year, in Spain during 2001, were estimated to be €10,189,
€7,662, and €5,614 respectively. The most important 
categories of cost during the ﬁrst year were acute hospi-
talisation and rehabilitation. During the second and third
year the most important categories of costs were drugs,
rehabilitation and tests. Stroke cost €1402.34 million to
the Spanish health care system, representing 4% of the
total public health care expenditure, €3197.55 million in
informal care and €392.95 million for productivity loss.
The total annual cost of all stroke related burden was
€4992.84 million. CONCLUSIONS: Stroke is a leading
public health problem in Spain in term of the economic
burden of disease. Given the magnitude of these costs,
investigation of the cost-effectiveness of different inter-
ventions for stroke should become a priority.
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OBJECTIVES: The risk of VTE after hip fracture surgery
has been clearly demonstrated by randomized clinical
trials designed for the registration of a new anti-
thrombotic agent. Nevertheless as the diagnosis of VTE
was based on a systematic venography which is not rou-
tinely performed in current practice, real life data based
on the occurence of clinical events are needed from both
an epidemiological and economic point of view.
METHODS: The VEEP (VEnous Embolism in hiP frac-
ture) cohort study was a prospective cohort study run in
two sizeable French public hospitals. During a 1-year
period, patients hospitalized for hip fracture were con-
secutively included and followed up for three months.
Resource use data concerning type of surgery, anti-throm-
botic treatments (preventive, curative) and clinical events
(Deep Vein Thrombosis, Pulmonary Embolism, bleed-
ings) were collected. RESULTS: One hundred sixty-nine
patients were included in the cohort study (mean age 84.6
years, 82% female). History of previous VTE was found
in 15% of the patients. Mean length of stay in acute care
was 16.1 days (+/-11). Mean length of stay in rehabili-
tation unit was 41.6 days (+/-22.7). A total of 162
patients received an antithrombotic treatment post-oper-
atively (in most of cases a low molecular weight heparin).
The cumulative rate of VTE clinically suspected and con-
ﬁrmed by echo-doppler was higher than expected (13.6%
at 3 months) and 80% of the VTE events occur after dis-
charge from acute care. Only one pulmonary embolism
was reported. Length of stay was signiﬁcantly higher in
patients having experienced a VTE (nine additional days
on an average) leading to substantial additional costs.
CONCLUSION: Despite standard antithrombotic pro-
phylaxis the risk of clinical VTE is high after hip fracture
surgery and even higher after the acute phase, highlight-
ing the need for more effective preventive therapies.
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OBJECTIVE: To project the life expectancy (LE) and
costs of treating patients with diabetes, hypertension, and
microalbuminuria with irbesartan 300mg. METHODS:
A long-term Markov model simulated progression from
microalbuminuria to nephropathy, doubling of serum 
creatinine, end-stage renal disease (ESRD), and all-cause
